Back to Browse Journals » Therapeutics and Clinical Risk Management » Volume 3 » Issue 4

Current treatment options in the management of chronic prostatitis

Authors Alain Jean Duclos, Chun-Te Lee, Daniel Arthur Shoskes

Published 15 September 2007 Volume 2007:3(4) Pages 507—512

Alain Jean Duclos, Chun-Te Lee, Daniel Arthur Shoskes

Glickman Urological Institute, The Cleveland Clinic, 9500 Euclid Ave, Cleveland OH 44195, USA

Abstract: Chronic prostatitis is a disease with an unknown etiology that affects a large number of men. The optimal management for category III chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) is unknown. The recent years have seen a significant increase in research efforts to understand, classify and treat CP/CPPS. Standard treatment usually consists of prolonged courses of antibiotics, even though well-designed clinical trials have failed to demonstrate their efficacy. Recent treatment strategies with some evidence of efficacy include: alpha-blockers, anti-inflammatory agents, hormonal manipulation, phytotherapy (quercetin, bee pollen), physiotherapy and chronic pain therapy. A stepwise, multimodal approach can be successful for the majority of patients who present with this difficult condition.

Keywords: prostatitis, chronic, treatment, management, CPPS

Download Article [PDF] 

Readers of this article also read:

Effect of surface roughness on osteogenesis in vitro and osseointegration in vivo of carbon fiber-reinforced polyetheretherketone–nanohydroxyapatite composite

Deng Y, Liu X, Xu A, Wang L, Luo Z, Zheng Y, Deng F, Wei J, Tang Z, Wei S

International Journal of Nanomedicine 2015, 10:1425-1447

Published Date: 17 February 2015

Treatment of premenstrual dysphoric disorder (PMDD) with a novel formulation of drospirenone and ethinyl estradiol

Domenico De Berardis, Nicola Serroni, Rosa Maria Salerno, Filippo Maria Ferro

Therapeutics and Clinical Risk Management 2007, 3:585-590

Published Date: 15 September 2007

Bisoprolol in the treatment of chronic heart failure: from pathophysiology to clinical pharmacology and trial results

Marco Metra, Savina Nodari, Tania Bordonali, Patrizia Milani, Carlo Lombardi, et al

Therapeutics and Clinical Risk Management 2007, 3:569-578

Published Date: 15 September 2007

Montelukast in the management of allergic rhinitis

Jaime A Lagos, Gailen D Marshall

Therapeutics and Clinical Risk Management 2007, 3:327-332

Published Date: 15 May 2007

Natalizumab: A new treatment for relapsing remitting multiple sclerosis

Michael Hutchinson

Therapeutics and Clinical Risk Management 2007, 3:259-268

Published Date: 15 May 2007

Editorial || FREE PAPER ||

Garry M Walsh

Therapeutics and Clinical Risk Management 2007, 3:211-212

Published Date: 15 May 2007

Skin and skin structure infections: treatment with newer generation fluoroquinolones

Philip Giordano, Kurt Weber, Gail Gesin, Jason Kubert

Therapeutics and Clinical Risk Management 2007, 3:309-317

Published Date: 15 May 2007

Dapoxetine, a novel selective serotonin transport inhibitor for the treatment of premature ejaculation

Muammer Kendirci, Emad Salem, Wayne JG Hellstrom

Therapeutics and Clinical Risk Management 2007, 3:277-289

Published Date: 15 May 2007

Diagnosis and treatment of chronic rhinosinusitis: focus on intranasal Amphotericin B

Eugene B Kern, David Sherris, Angelos M Stergiou, Laura M Katz, Lisa C Rosenblatt, Jens Ponikau

Therapeutics and Clinical Risk Management 2007, 3:319-325

Published Date: 15 May 2007